专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明公开

KR1020110106354A 트리아진 유도체들과 인슐린의 조합물 및 당뇨병을 치료하기 위한 이의 용도 有权
标题翻译：胰岛素与TRIAZINE衍生物的组合及其用于治疗糖尿病
公开(公告)号：KR1020110106354A
公开(公告)日：2011-09-28
申请号：KR1020117016022
申请日：2009-11-13
申请人： 뽁셀 에스아에스
发明人： 메상쥬,디디에 , 크라보,다니엘 , 오데트,애닉
IPC分类号： A61K31/53 , A61K38/28 , A61P3/10 , A61P3/00
CPC分类号： A61K38/28 , A61K31/53 , A61K45/06 , Y10S514/866 , A61K2300/00
摘要： The invention relates to a composition for use as a medicament comprising insulin in combination with at least one compound of formula (I) wherein the radicals R1 to R6 have the meaning according to claim 1, and/or physiologically acceptable salts thereof. Another object of the invention concerns a pharmaceutical composition comprising as active ingredients effective amounts of insulin and at least one compound of formula (I), together with pharmaceutically tolerable adjuvants, for the prophylactic or therapeutic treatment and/or monitoring of physiological and/or pathological conditions that are associated with insulin resistance. The invention also relates to a pharmaceutical package comprising insulin in a first dosage unit and at least one compound of formula (I) in a second dosage unit.

62. 发明授权

KR101038616B1 뼈 및 연골 질환의 치료, 예방, 또는 완화용 약제학적 조성물 失效
标题翻译：用于治疗，预防或治疗骨质疏松疾病的药物组合物
公开(公告)号：KR101038616B1
公开(公告)日：2011-06-03
申请号：KR1020110023372
申请日：2011-03-16
申请人： 박재우
发明人： 박재우
IPC分类号： A61K35/28 , A61K31/728 , A61K35/16 , A61K35/19 , A61K47/02 , A61K38/19 , A61K38/28 , A61K9/00
CPC分类号： A61K31/728 , A61K9/0019 , A61K35/16 , A61K35/19 , A61K35/28 , A61K38/19 , A61K38/28 , A61K47/02 , A61K2300/00
摘要： PURPOSE: A pharmaceutical composition for preventing, treating, or relieving bone or cartilage diseases is provided to regenerate bone and cartilage without side effects. CONSTITUTION: A pharmaceutical composition for preventing, treating, or relieving bone diseases or cartilage diseases contains 4-15 weight parts of adipose stem cells, 1-10 weight parts of platelet rich plasma, 0.1-0.4 weight parts of 1-5% calcium chloride, and 0.5-2 weight parts of hyaluronic acid. The bone disease is avascular necrosis of head of femur. The cartilage disease is degenerative arthritis.
摘要翻译：目的：提供一种用于预防，治疗或缓解骨或软骨疾病的药物组合物，用于再生骨和软骨，无副作用。构成：用于预防，治疗或缓解骨疾病或软骨疾病的药物组合物含有4-15重量份的脂肪干细胞，1-10重量份富血小板血浆，0.1-0.4重量份1-5％氯化钙，0.5-2重量份的透明质酸。骨病是股骨头无血管性坏死。软骨病是退行性关节炎。

63. 发明公开

KR1020110052664A 초속효성 인슐린의 용도 无效
标题翻译：超声波治疗胰岛素的使用
公开(公告)号：KR1020110052664A
公开(公告)日：2011-05-18
申请号：KR1020117004601
申请日：2009-08-11
申请人： 맨카인드 코포레이션
发明人： 리차드슨피터 , 보먼로버트에이 , 포토츠카엘리자베쓰 , 보스안데르스하사거 , 페트루치리차드 , 하워드켐벨 , 만알프레드
IPC分类号： A61K38/28 , A61P3/10
CPC分类号： A61K38/28 , A61K9/0021 , A61K9/0075 , A61K47/545
摘要： 본원은 초속효성 인슐린의 식사시 투여 및 하루 동안 기상 후 6시간 내에 인슐린 글라진의 제1 용량의 투여를 포함하는 초속효성 인슐린과 인슐린 글라진의 병용에 의해 고혈당증을 치료하는 개선된 방법을 개시한다.

64. 发明公开

KR1020110043686A 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드의 유사체 无效
标题翻译：葡萄糖依赖性胰岛素多肽的模拟物
公开(公告)号：KR1020110043686A
公开(公告)日：2011-04-27
申请号：KR1020117003753
申请日：2009-08-07
申请人： 입센 파마 에스.에이.에스.
发明人： 동젱신
IPC分类号： C07K14/62 , C07K14/46 , A61K38/28 , A61P31/10
CPC分类号： C07K14/645 , A61K38/00 , C07K14/605 , C07K19/00
摘要： 본 발명은 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드의 새로운 일련의 유사체, 상기 화합물을 포함하는 약학 조성물, 및 인슐린 비의존성 당뇨병 및 비만과 같은 GIP-수용체에 의해 매개되는 증상의 치료를 위한 GIP-수용체 작용제 또는 길항제로서의 상기 화합물의 용도에 관한 것이다.

65. 发明公开

KR1020100077195A 경구 투여가능한 고형 약제학적 조성물 및 그 제조방법 有权
标题翻译：一种营养可行的固体药物组合物及其制备方法
公开(公告)号：KR1020100077195A
公开(公告)日：2010-07-07
申请号：KR1020107010449
申请日：2008-10-16
申请人： 바이오콘 리미티드
发明人： 케드카르,아난드 , 랑가파,샤랏,쿠마,몰라푸라 , 수브라마니,라메쉬 , 데이브,니테쉬 , 라다크리쉬난,드베쉬 , 상카,썬다레쉬 , 치브큐라,수드히어 , 라마크리쉬나,란지스 , 머시,샨무감,탄다바 , 파이,해리쉬,벤카트라만 , 센굽타,닐란잔 , 멜라코드,라마크리슈난 , 아이어,해리쉬
IPC分类号： A61K9/20 , A61K38/28 , A61K47/48 , A61K47/14
CPC分类号： A61K9/2077 , A61K9/1617 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K38/28 , A61K47/542 , A61K47/543 , A61K9/20 , A61K47/14 , A61K47/50
摘要： The invention relates to improvised pharmaceutical compositions permitting ingestion via oral delivery of proteins/peptides or their conjugates, and/or cation-insulin conjugate complexes demonstrating desirable pharmacokinetic profiles and potency in efficacy models of diabetes in dogs and humans. A preferred formulation comprises 0.01%-20% w/w of insulin, insulin compound conjugates and/or cation insulin conjugates, 10%-60% w/w of one or more fatty acid components selected from saturated or unsaturated C4-C12 fatty acids and/or salts of such fatty acids and additionally contains optimal amounts of other pharmaceutically suitable polymer excipients which permit improved solubility, dissolution rate and effective bioavailability of poorly water soluble compositions and consistent in-vivo release profiles upon scalability during manufacture. A further aspect of the invention features the process of preparing the aforesaid formulations.
摘要翻译：本发明涉及通过口服递送蛋白质/肽或其缀合物和/或阳离子 - 胰岛素缀合物复合物的临时药物组合物，其证明了狗和人类糖尿病功效模型中所需的药代动力学特征和效力。优选的制剂包含0.01％-20％w / w的胰岛素，胰岛素化合物缀合物和/或阳离子胰岛素缀合物，10％-60％w / w的一种或多种选自饱和或不饱和C 4 -C 12脂肪酸的脂肪酸组分和/或这种脂肪酸的盐，并且另外含有最佳量的其它药学上合适的聚合物赋形剂，其允许改善水溶性差的组合物的溶解度，溶解速率和有效的生物利用度，并且在制造期间具有可扩展性的一致的体内释放曲线。本发明的另一方面的特征在于制备上述制剂的方法。

66. 发明公开

KR1020100022022A 자가면역 질환 및 암을 치료하기 위한 의약 및 방법 无效
标题翻译：治疗自身免疫性疾病和癌症的药物和方法
公开(公告)号：KR1020100022022A
公开(公告)日：2010-02-26
申请号：KR1020097024512
申请日：2008-04-24
申请人： 다이아미드 쎄라퓨틱스 아베
发明人： 루드빅손조니 , 카사스로사우라 , 파레스조마리아 , 에센-몰러앤더스
IPC分类号： A61K38/28 , A61K39/00 , A61P37/02 , A61P5/50
CPC分类号： A61K39/0008 , A61K2039/55505
摘要： The present invention relates to methods and formulations for GAD-vaccination to evoke a systemic effect rather that a GAD-specific effect. The present invention may therefore be used in the treatment of disease in humans not bearing on a GAD-specific effect. The invention includes a method to treat an autoimmune disease or disorder by administering at least one sequestered autoantigen in a prime and boost regimen for sensitization purposes followed by a boost for treatment purposes. This may be done upon diagnosis. Examples of sequestered autoantigens include: GAD65, GAD67, Pro-Insulin, Basic Myelin Protein, MOG and Chondrotoin II. The present invention relates to medications and methods for treatment of autoimmune disease within six months from diagnosis.
摘要翻译：本发明涉及用于GAD-疫苗接种以引起全身效应而不是GAD特异性效应的方法和制剂。因此，本发明可用于治疗不具有GAD特异性作用的人的疾病。本发明包括一种治疗自身免疫性疾病或病症的方法，其通过在促炎方案中施用至少一种隔离自身抗原用于敏化目的，然后进行治疗目的的促进。这可以在诊断后进行。螯合自身抗原的实例包括：GAD65，GAD67，Pro-Insulin，髓磷脂髓原蛋白，MOG和软骨素Ⅱ。本发明涉及在诊断后六个月内治疗自身免疫性疾病的药物和方法。

67. 发明公开

KR1020090077066A 입자 형성 无效
标题翻译：颗粒形成
公开(公告)号：KR1020090077066A
公开(公告)日：2009-07-14
申请号：KR1020097009261
申请日：2007-10-05
申请人： 뉴사우스 이노베이션즈 피티와이 리미티드
发明人： 포스터닐러셀 , 펭츠시로데릭
IPC分类号： A61K9/16 , B01J2/02 , B01J2/04 , A61K38/28
CPC分类号： A61K9/14 , A61K9/1682 , B01J2/006 , Y10T428/2982
摘要： A process for producing particles of a substance is described wherein a solution of the substance in a solvent is delivered in at least one shot into a supercritical fluid. The supercritical fluid is a non-solvent for the substance and is miscible with the solvent. Particles of the substance distributed in a mixture of the solvent and the supercritical fluid are formed.
摘要翻译：描述了一种用于生产物质颗粒的方法，其中将物质在溶剂中的溶液至少一次喷射到超临界流体中。超临界流体是该物质的非溶剂，并与溶剂混溶。形成分散在溶剂和超临界流体的混合物中的物质的颗粒。

68. 发明公开

KR1020080064750A 면역글로불린 단편을 이용한 인슐린분비 펩타이드 약물결합체 有权
标题翻译：使用免疫抑制蛋白片段的胰岛素复合物
公开(公告)号：KR1020080064750A
公开(公告)日：2008-07-09
申请号：KR1020080001479
申请日：2008-01-04
申请人： 한미사이언스 주식회사
发明人： 송대해 , 임창기 , 송태헌 , 김영훈 , 권세창 , 이관순 , 정성엽 , 최인영
IPC分类号： A61K38/28 , A61K38/16
CPC分类号： C07K14/57563 , A61K38/00 , A61K47/6835 , C07K14/605
摘要： An insulinotropic peptide conjugate is provided to maintain the in-vivo activity relatively high and show remarkably increased blood half-life, thereby being usefully used for developing long acting formulations of various peptide drugs. An insulinotropic peptide conjugate comprises an insulinotropic peptide and an immunoglobulin Fc region, which are linked by a non-peptidyl polymer, wherein the non-peptidyl polymer is selected from the group consisting of polyethylene glycol, polypropylene glycol, copolymers of ethylene glycol and propylene glycol, polyoxyethylated polyols, polyvinyl alcohol, polysaccharides, dextran, polyvinyl ethyl ether, biodegradable polymers, lipid polymers, chitins, hyaluronic acid, and combinations thereof, and wherein one end of the non-peptidyl polymer is linked to an amino acid residue other than the N-terminus of the insulinotropic peptide. An insulinotropic peptide derivative is represented by a formula(1) of R1-X-Y-Z-R2, wherein R1 is selected from the group consisting of histidine, des-amino-histidyl, N-dimethyl-histidyl, beta-hydroxy imidazopropyl and 4-imidazoacetyl; R2 is selected from the group consisting of NH2, OH and Lys; X is selected from the group consisting of GIy-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-RS-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg- Leu-Phe-Ile-Glu-Trp-Leu-R4-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser, GIy-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-R3-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-R4-Asn-Gly-Gly, and Ser-Asp-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-RS-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg- Leu-Phe-Ile-Glu-Trp-Leu-R4-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser; R3 is selected from the group consisting of Lys, Ser and Arg; R4 is selected from the group consisting of Lys, Ser and Arg; Y is polyethylene glycol, polypropylene glycol, copolymers of ethylene glycol and propylene glycol, polyoxyethylated polyols, polyvinyl alcohol, polysaccharides, dextran, polyvinyl ethyl ether, biodegradable polymers, lipid polymers, chitins, hyaluronic acid, and combinations thereof; and Z is an immunoglobulin Fc region. A pharmaceutical composition for treating diabetes, obesity, acute coronary syndrome, or polycystic ovary syndrome comprises the peptide conjugate. Further, the insulinotropic peptide is selected from GLP-1, exendin-3, exendin-4 or agonist there, derivative, fragment, variant and a mixture thereof.
摘要翻译：提供促胰岛素肽缀合物以维持体内活性相对较高并且显示出显着增加的血液半衰期，从而有用地用于开发各种肽药物的长效制剂。促胰岛素肽缀合物包含通过非肽基聚合物连接的促胰岛素肽和免疫球蛋白Fc区，其中非肽基聚合物选自聚乙二醇，聚丙二醇，乙二醇和丙二醇的共聚物聚氧乙烯化多元醇，聚乙烯醇，多糖，葡聚糖，聚乙烯基乙醚，生物可降解聚合物，脂质聚合物，壳多糖，透明质酸及其组合，其中非肽基聚合物的一端与除促胰岛素肽的N-末端。促胰岛素肽衍生物由R1-XYZ-R2的式（1）表示，其中R1选自组氨酸，去氨基 - 组氨酰基，N-二甲基 - 组氨酰基，β-羟基咪唑丙基和4-咪唑乙酰基 ; R2选自NH2，OH和Lys; X选自Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-RS-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe- Ile-Glu-Trp-Leu-R4-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser，Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp- Leu-Ser-R3-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-R4-Asn-Gly-Gly和Ser-Asp-Gly-Thr -Phe-Thr-Ser-Asp-Leu-Ser-RS-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-R4-Asn-Gly-Gly -Pro-SER-SER-甘氨酸 - 丙氨酸 - 脯氨酸 - 脯氨酸 - 脯氨酸 - 丝氨酸; R3选自Lys，Ser和Arg; R4选自Lys，Ser和Arg; Y是聚乙二醇，聚丙二醇，乙二醇和丙二醇的共聚物，聚氧乙烯化多元醇，聚乙烯醇，多糖，葡聚糖，聚乙烯基乙醚，生物降解聚合物，脂质聚合物，壳多糖，透明质酸及其组合; Z是免疫球蛋白Fc区。用于治疗糖尿病，肥胖症，急性冠状动脉综合征或多囊卵巢综合征的药物组合物包含肽缀合物。此外，促胰岛素肽选自GLP-1，毒蜥外泌肽-3，毒蜥外泌肽-4或其中的激动剂，衍生物，片段，变体及其混合物。

69. 发明公开

KR1020070027747A 대사 질환의 치료 방법 및 시약 无效
标题翻译：用于治疗代谢性疾病的方法和试剂
公开(公告)号：KR1020070027747A
公开(公告)日：2007-03-09
申请号：KR1020077002096
申请日：2005-06-29
申请人： 콤비네이토릭스, 인코포레이티드
发明人： 리,마가렛,에스. , 짐메르만,그란트,알. , 피넬리,앨리스,린 , 그라우,다니엘 , 키스,커티스 , 니콜,엠.,제임스
IPC分类号： A61K31/60 , A61K38/28 , A61P3/00 , A61K31/19
CPC分类号： A61K38/28 , A61K31/19 , A61K31/192 , A61K31/56 , A61K31/60 , A61K31/603 , A61K31/64 , A61K33/28 , A61K45/06 , Y10S514/866 , A61K2300/00
摘要： The invention features compositions, methods, and kits for the treatment of metabolic disorders such as diabetes and obesity. ® KIPO & WIPO 2007
摘要翻译：本发明的特征在于用于治疗代谢性疾病如糖尿病和肥胖症的组合物，方法和试剂盒。 ®KIPO＆WIPO 2007

70. 发明公开

KR1020060110353A 제2형 당뇨병 환자에서 혈청 프로인슐린 농도의 감소 방법 无效
标题翻译：降低2型糖尿病血清胰蛋白酶水平的方法
公开(公告)号：KR1020060110353A
公开(公告)日：2006-10-24
申请号：KR1020067013980
申请日：2005-01-10
申请人： 맨카인드 코포레이션
发明人： 체트햄웨이맨웬델 , 푸에츠너안드레아스 , 보스앤더스하세거
IPC分类号： A61K38/28 , A61P3/10
CPC分类号： A61K38/28
摘要： Methods are provided for reducing serum proinsulin levels, lessening post-prandial pancreatic stress, and reducing risk factors for atherosclerosis in subjects with diabetes mellitus, type 2. The method includes administration of insulin in a manner that mimics the meal-related first phase insulin response, using a dose sufficient to reduce serum levels of proinsulin. In some embodiments of the method insulin administration is commenced early in the course of the disease. Mimicking first phase kinetics, peak serum insulin levels can be reached within about 18 minutes of administration. In increasingly preferred embodiments peak serum insulin levels can be reached within about 15, 12, or 10 minutes of administration. Serum insulin levels return to baseline within about two hours of administration.
摘要翻译：提供了用于降低血清胰岛素原水平，减轻餐后胰腺压力并降低患有糖尿病2型的受试者的动脉粥样硬化的危险因素的方法。该方法包括以模拟与膳食相关的第一阶段胰岛素反应的方式施用胰岛素，使用足以降低胰岛素原血清水平的剂量。在该方法的一些实施方案中，胰岛素给药在疾病过程的早期开始。模拟第一相动力学，可在约18分钟内达到峰值血清胰岛素水平。在越来越优选的实施方案中，可以在给药的约15,12或10分钟内达到峰值血清胰岛素水平。血清胰岛素水平在约2小时内恢复至基线。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式